MXCT - MAXCYTE, INC.

2.92
0.040   1.370%

Share volume: 868,533
Last Updated: 04-28-2025
Business Services/Services – Research, Development, Testing Labs: -0.07%

PREVIOUS CLOSE
CHG
CHG%
$2.88
0.04
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
20%
Profitability 0%
Dept financing 5%
Liquidity 73%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.49%
1 Month
5.49%
3 Months
-18.64%
6 Months
-18.64%
1 Year
-18.64%
2 Year
-18.64%
Key data
Stock price
$2.92
P/E Ratio 
0.00
DAY RANGE
$2.83 - $2.96
EPS 
-$0.10
52 WEEK RANGE
$2.21 - $3.69
52 WEEK CHANGE
-$18.64
MARKET CAP 
438.807 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$661,324
AVERAGE 30 VOLUME 
$686,702
Company detail
CEO: Douglas A. Doerfler
Region: US
Website: maxcyte.com
Employees: 80
IPO year: 2019
Issue type:
Market: XNAS
Industry: Business Services/Services – Research, Development, Testing Labs
Sector: Services

MaxCyte, Inc. engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Recent news
loading